ChemoCentryx Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of ChemoCentryx Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 20 Oct 2021 | Lorem |
| ChemoCentryx’s avacopan in ANCA-associated vasculitis has contentious FDA approval nod though certain patient groups stand to strongly benefit | 23 Aug 2021 | Manasi Vaidya |
| ChemoCentryx’s CCX140 carries unclear expectations in FSGS with limited proteinuria reduction in diabetic nephropathy that is hard to extrapolate, experts say | 26 Dec 2019 | Manasi Vaidya |
| ChemoCentryx’s Phase III avacopan splits experts on importance of superiority data for payer coverage in 1L ANCA vasculitis use, but 26-week noninferiority data expected | 07 Oct 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward